Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Terrien

Cardiovascular Disease Loris, SC Medical Doctor

NPI 1013928910 CMS profile 648552

3485 Mitchell St, Loris, SC 29569

Open in the dashboard

General payments

$49,834

102 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Terrien of Loris, SC is reported in the CMS Open Payments database as having received $49,834 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $291 7
2024 General $5,967 11
2023 General $14,936 51
2022 General $2,638 17
2021 General $5,056 4
2020 General $375 1
2019 General $20,570 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Terrien
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Edward Terrien were reported at $291. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Edward Terrien Cardiovascular Disease median Middle half National median
2019 $20,570 $450 $127–$1,392 $163
2020 $375 $242 $77–$751 $114
2021 $5,056 $335 $101–$1,037 $132
2022 $2,638 $395 $121–$1,211 $149
2023 $14,936 $443 $136–$1,283 $160
2024 $5,967 $450 $136–$1,323 $164
2025 $291 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $23,371 42 payments
  2. Medtronic Vascular, Inc. $20,945 12 payments
  3. Penumbra, Inc. $2,400 1 payment
  4. Boston Scientific Corporation $1,381 12 payments
  5. Abbott Laboratories $425 6 payments
  6. Inari Medical, Inc. $294 6 payments
  7. Shockwave Medical, Inc $269 3 payments
  8. Abiomed $207 3 payments
  9. HeartFlow, Inc. $90 1 payment
  10. Lantheus Medical Imaging, Inc. $87 1 payment
  11. Other $366 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,681 19 payments
  2. Travel and Lodging $5,102 12 payments
  3. Food and Beverage $3,037 70 payments
  4. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. CoreValve Evolut Transcatheter Valve Systems $20,945 12 payments
  2. COREVALVE EVOLUT R $20,661 37 payments
  3. CoreValve Evolut Transcatheter Valve Systems $2,656 3 payments
  4. Indigo System $2,400 1 payment
  5. CT THROMBECTOMY SYSTEM KIT $294 6 payments
  6. FLOWTRIEVER CATHETER, S $294 6 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $188 2 payments
  8. Impella $185 2 payments
  9. COROFLOW $145 1 payment
  10. MITRACLIP $127 2 payments
  11. Other $968 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

420

Median for Cardiology: 2,533

Drug cost

$81,254

Median for Cardiology: $485,213

Branded share of claims

28.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 47 $65,983
Repatha Sureclick Evolocumab Brand 11 $11,582
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 21 $667
Metoprolol Succinate Generic 60 $633
Famotidine Generic 51 $613
Losartan Potassium Generic 35 $445
Clopidogrel Clopidogrel Bisulfate Brand 40 $335
Atorvastatin Calcium Generic 35 $291
Carvedilol Generic 20 $164
Pantoprazole Sodium Generic 22 $120

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$47,847

Medicare's payments for the services billed

Medicare patients

1,255

Average age 75

Services billed

1,758

629 women, 626 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 35%
Atrial fibrillation 35%
Chronic kidney disease 32%
Diabetes 31%
Depression 28%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record